Mantle Cell Lymphoma | Specialty

The OncLive Mantle Cell Lymphoma condition center page is a comprehensive resource for clinical news and expert insights on mantle cell lymphoma treatment. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, therapeutic advances, and ongoing research in mantle cell lymphoma.

Frontline Lenalidomide/Rituximab Combo Warrants Further Investigation in MCL

January 11th 2018

Jia Ruan, MD, PhD, discusses the pivotal analysis of the combination of lenalidomide plus rituximab, as well as the next steps for this regimen in the field of mantle cell lymphoma.

Dr. Ruan on Lenalidomide Plus Rituximab in MCL

January 8th 2018

Jia Ruan, MD, PhD, associate professor of clinical medicine, Weill Cornell, NewYork-Presbyterian Hospital, discusses the combination of lenalidomide (Revlimid) plus rituximab (Rituxan) in mantle cell lymphoma.

Dr. O'Connor on Acalabrutinib Versus Ibrutinib in MCL

January 3rd 2018

Owen O'Connor, MD, PhD, Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center, discusses acalabrutinib (Calquence) versus ibrutinib (Imbruvica) for the treatment of patients with mantle cell lymphoma

Long-Term Ibrutinib Follow-up Demonstrates Continued Efficacy in MCL

January 3rd 2018

More than one-quarter of patients with relapsed/refractory mantle cell lymphoma remained progression free and nearly half were alive at 3 years when treated with the BTK inhibitor ibrutinib (Imbruvica).

Highlights from ASH 2017: Mantle Cell Lymphoma

December 23rd 2017

Investigational Treatment in Mantle Cell Lymphoma

December 23rd 2017

Future Therapy: Bruton's TKI Containing Combinations in MCL

December 23rd 2017

Allogeneic Transplantation in Mantle Cell Lymphoma

December 23rd 2017

Acalabrutinib in Relapsed Mantle Cell Lymphoma

December 23rd 2017

Ibrutinib in Relapsed Mantle Cell Lymphoma

December 23rd 2017

Understanding Relapse in Mantle Cell Lymphoma

December 23rd 2017

Maintenance Therapy in Mantle Cell Lymphoma

December 23rd 2017

Considerations for Autologous Stem Cell Transplantation

December 23rd 2017

Induction Therapy for Mantle Cell Lymphoma

December 23rd 2017

The Watch-and-Wait Approach in Mantle Cell Lymphoma

December 23rd 2017

The Value of MIPI and Ki-67 in Mantle Cell Lymphoma

December 23rd 2017

Considerations for Diagnosing Mantle Cell Lymphoma

December 23rd 2017

Classifying Mantle Cell Lymphoma

December 23rd 2017

Dr. Wang Discusses Acalabrutinib in MCL

December 22nd 2017

Michael Wang, MD, professor in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, discusses acalabrutinib (Calquence) in mantle cell lymphoma.

NICE Recommends Ibrutinib for Relapsed/Refractory MCL

December 16th 2017

The United Kingdom's National Institute for Health Care and Excellence has published new guidelines recommending ibrutinib as treatment for patients with relapsed/refractory mantle cell lymphoma.